Total Payments
$88,237
2024 Payments
$5,137
Companies
13
Transactions
87
Medicare Patients
888
Medicare Billing
$188,822
Payment Breakdown by Category
Consulting$51,127 (57.9%)
Other$24,349 (27.6%)
Travel$6,763 (7.7%)
Research$3,827 (4.3%)
Food & Beverage$2,158 (2.4%)
Education$12.29 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $51,127 | 15 | 57.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,896 | 10 | 27.1% |
| Travel and Lodging | $6,763 | 27 | 7.7% |
| Unspecified | $3,827 | 4 | 4.3% |
| Food and Beverage | $2,158 | 28 | 2.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $453.74 | 2 | 0.5% |
| Education | $12.29 | 1 | 0.0% |
Payments by Type
General
$84,411
83 transactions
Research
$3,827
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kite Pharma, Inc. | $40,092 | 34 | $0 (2023) |
| ADC Therapeutics America, Inc. | $10,003 | 6 | $0 (2022) |
| Celgene Corporation | $8,515 | 7 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $6,965 | 6 | $0 (2017) |
| Incyte Corporation | $6,881 | 12 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $4,681 | 4 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $3,574 | 4 | $0 (2024) |
| Genentech USA, Inc. | $3,058 | 4 | $0 (2018) |
| ABBVIE INC. | $1,650 | 1 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $1,260 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,137 | 7 | E.R. Squibb & Sons, L.L.C. ($4,681) |
| 2023 | $20,598 | 21 | Kite Pharma, Inc. ($13,716) |
| 2022 | $22,794 | 16 | Kite Pharma, Inc. ($11,141) |
| 2021 | $3,000 | 2 | Kite Pharma, Inc. ($3,000) |
| 2020 | $6,095 | 6 | Kite Pharma, Inc. ($4,020) |
| 2019 | $13,718 | 16 | Kite Pharma, Inc. ($8,215) |
| 2018 | $8,273 | 10 | AstraZeneca Pharmaceuticals LP ($3,283) |
| 2017 | $8,623 | 9 | Novartis Pharmaceuticals Corporation ($6,965) |
All Payment Transactions
87 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,865.00 | General |
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $59.43 | General |
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $27.01 | General |
| 09/30/2024 | AstraZeneca Pharmaceuticals LP | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $290.70 | General |
| 09/30/2024 | TAIHO ONCOLOGY, INC. | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $163.04 | General |
| 09/30/2024 | TAIHO ONCOLOGY, INC. | — | Travel and Lodging | Cash or cash equivalent | $1.83 | General |
| 03/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,730.00 | General |
| 05/26/2023 | Kite Pharma, Inc. | — | Travel and Lodging | In-kind items and services | $212.38 | General |
| 04/18/2023 | Kite Pharma, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,140.00 | General |
| 04/18/2023 | Kite Pharma, Inc. | — | Travel and Lodging | In-kind items and services | $193.79 | General |
| 04/13/2023 | Kite Pharma, Inc. | — | Travel and Lodging | In-kind items and services | $13.10 | General |
| 04/11/2023 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $123.26 | General |
| 03/31/2023 | Kite Pharma, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,950.00 | General |
| 03/28/2023 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $107.50 | General |
| 03/13/2023 | Kite Pharma, Inc. | — | Travel and Lodging | In-kind items and services | $26.20 | General |
| 03/09/2023 | Kite Pharma, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,950.00 | General |
| 01/12/2023 | Incyte Corporation | JAKAFI (Drug) | Consulting Fee | Cash or cash equivalent | $4,850.00 | General |
| Category: Hematology/Oncology | ||||||
| 01/12/2023 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $103.85 | General |
| Category: Hematology/Oncology | ||||||
| 01/12/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $85.87 | General |
| Category: Hematology/Oncology | ||||||
| 01/12/2023 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $60.00 | General |
| Category: Hematology/Oncology | ||||||
| 01/12/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $52.18 | General |
| Category: Hematology/Oncology | ||||||
| 01/12/2023 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $39.30 | General |
| Category: Hematology/Oncology | ||||||
| 01/12/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.01 | General |
| Category: Hematology/Oncology | ||||||
| 01/12/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $3.88 | General |
| Category: Hematology/Oncology | ||||||
| 01/11/2023 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $1,307.41 | General |
| Category: Hematology/Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-122-DLBCL-001 - A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | Celgene Corporation | $1,524 | 1 |
| CC-122-DLBCL-001 | Celgene Corporation | $1,488 | 1 |
| A PHASE IbII STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA | F. Hoffmann-La Roche AG | $814.63 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 237 | 578 | $239,030 | $56,589 |
| 2022 | 6 | 217 | 506 | $192,600 | $42,884 |
| 2021 | 4 | 193 | 482 | $180,710 | $41,042 |
| 2020 | 7 | 241 | 680 | $233,295 | $48,307 |
Total Patients
888
Total Services
2,246
Medicare Billing
$188,822
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 87 | 229 | $113,355 | $26,914 | 23.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 96 | 164 | $61,500 | $12,468 | 20.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 18 | 105 | $37,275 | $10,563 | 28.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 21 | 65 | $16,250 | $4,347 | 26.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 15 | 15 | $10,650 | $2,297 | 21.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 102 | 260 | $97,500 | $20,477 | 21.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 20 | 97 | $34,435 | $8,310 | 24.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 45 | 67 | $33,165 | $8,033 | 24.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 47 | $11,750 | $2,819 | 24.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 15 | 15 | $10,650 | $2,339 | 22.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 17 | 20 | $5,100 | $906.36 | 17.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 115 | 312 | $117,000 | $25,408 | 21.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 18 | 86 | $30,530 | $7,554 | 24.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 28 | 49 | $24,255 | $6,170 | 25.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 32 | 35 | $8,925 | $1,909 | 21.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 115 | 342 | $128,250 | $22,756 | 17.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 22 | 134 | $47,570 | $12,129 | 25.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 22 | 113 | $28,250 | $7,079 | 25.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 13 | 13 | $9,230 | $1,920 | 20.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 17 | 19 | $9,405 | $1,841 | 19.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 33 | 37 | $4,980 | $1,600 | 32.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 19 | 22 | $5,610 | $982.16 | 17.5% |
About Dr. Iris Isufi, M.D
Dr. Iris Isufi, M.D is a Hematology & Oncology healthcare provider based in New Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/24/2008. The National Provider Identifier (NPI) number assigned to this provider is 1407021140.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Iris Isufi, M.D has received a total of $88,237 in payments from pharmaceutical and medical device companies, with $5,137 received in 2024. These payments were reported across 87 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($51,127).
As a Medicare-enrolled provider, Isufi has provided services to 888 Medicare beneficiaries, totaling 2,246 services with total Medicare billing of $188,822. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location New Haven, CT
- Active Since 04/24/2008
- Last Updated 05/18/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1407021140
Products in Payments
- Yescarta (Drug) $14,850
- JAKAFI (Drug) $6,881
- KYMRIAH (Biological) $6,407
- JCAR017 (Drug) $5,503
- CALQUENCE (Drug) $3,283
- Rituxan (Biological) $3,058
- CC-122 (Drug) $3,012
- Tecartus (Drug) $1,700
- Aliqopa (Drug) $1,260
- POLIVY (Biological) $814.63
- ADCETRIS (Biological) $182.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New Haven
Amer Zeidan
Hematology & Oncology — Payments: $934,438
Hematology & Oncology $934,438
Dr. Daniel Petrylak, M.d, M.D
Hematology & Oncology — Payments: $642,957
Hematology & Oncology $642,957
Cheryl Mensah, M.d, M.D
Hematology & Oncology — Payments: $236,631
Hematology & Oncology $236,631
Dr. Stacey Stein, Md, MD
Hematology & Oncology — Payments: $125,024
Hematology & Oncology $125,024
Walid Shaib, M.d, M.D
Hematology & Oncology — Payments: $89,344
Hematology & Oncology $89,344
Dr. Shalin Kothari, Md, MD
Hematology & Oncology — Payments: $22,139
Hematology & Oncology $22,139